You just read:

Daiichi Sankyo Presents Preliminary Phase 1 Data for HER3 Targeting ADC U3-1402 in Patients with EGFR Mutated Non-Small Cell Lung Cancer at 2019 ASCO Annual Meeting

News provided by

Daiichi Sankyo Company, Limited

31 May, 2019, 13:00 BST